Orion Oyj (OTCMKTS:ORINY) Announces Earnings Results

Orion Oyj (OTCMKTS:ORINY) posted its quarterly earnings results on Tuesday. The company reported $0.28 earnings per share (EPS) for the quarter, Zacks reports. Orion Oyj had a net margin of 23.01% and a return on equity of 39.49%. The firm had revenue of $463.41 million for the quarter.

Orion Oyj Stock Performance

Shares of OTCMKTS:ORINY opened at $27.03 on Thursday. The company has a quick ratio of 1.41, a current ratio of 2.42 and a debt-to-equity ratio of 0.25. The business has a 50 day moving average of $24.83 and a 200-day moving average of $25.12. Orion Oyj has a 12-month low of $17.50 and a 12-month high of $28.55. The stock has a market cap of $7.63 billion, a PE ratio of 21.45 and a beta of 0.24.

Analysts Set New Price Targets

Separately, Nordea Equity Research cut Orion Oyj to a “hold” rating in a research report on Tuesday, February 4th.

About Orion Oyj

Orion Oyj develops, manufactures, and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients (APIs) in Finland, Scandinavia, rest of Europe, North America, and internationally. The company provides prescription drugs and self-care products, which includes Nubeqa for the treatment of prostate cancer; Precedex, Dexdor, and Precedex for human use; Burana for inflammatory pain; Divina series for menopausal symptoms; Trexan for rheumatoid arthritis and cancer; Stalevo, Entacapone, and Comtess/Comtan for Parkinson’s disease; Biosimilars for rheumatoid arthritis and inflammatory bowel diseases; and Simdax for acute decompensated heart failure, as well as Fareston for breast cancer.